Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,844 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Depressed Clear all

Conditions: Pelvic Pain, Depression, Anxiety
Interventions: Brief ACT for Pelvic Pain; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Postpartum Depression
Interventions: SAGE-547, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more

Conditions: Stress, Depression
Interventions: Stress management; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression, Anxiety, Psychosis
Interventions: Participatory technology development, Usual Care; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
Interventions: TNX-601 ER, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 27
States / cities: Little Rock, Arkansas • Bellflower, California • Glendale, California + 24 more

Conditions: Depressive Disorder, Major
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 39
States / cities: Rogers, Arkansas • Bellflower, California • Garden Grove, California + 34 more

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: ORG 34517; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: CERC-301, Placebo; Drug · Other
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more

Conditions: Bipolar Depression, Major Depressive Disorder
Interventions: Lumateperone, Placebos; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Garden Grove, California • Oceanside, California • Sherman Oaks, California + 10 more

Conditions: PTSD, Depression, Substance Use Disorder, Traumatic Brain Injury
Interventions: WEB-ED+ Treatment Arm; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 1,312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Major Depressive Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 30
States / cities: Birmingham, Alabama • Cerritos, California • Encino, California + 27 more

Conditions: Depression Disorders, Anxiety Disorders
Interventions: Not listed
Lead sponsor: Deliberate Solutions Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Distress, Cancer, Chemotherapy Effect
Interventions: Mindfulness meditation program (administered via mobile app), Progressive muscle relaxation (via mobile app); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Depression, Dual Diagnosis, Drug Addiction
Interventions: Creatine monohydrate; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: 1. Major Depressive Disorder
Interventions: Supplemental TMS, Standard Medication Monotherapy; Device · Drug
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions: Coordinated Specialty Care (CSC); Other
Lead sponsor: Indiana University; Other
Eligibility: 16 Years to 35 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more

Conditions: Depression, Anxiety
Interventions: Scoring Your College Goals Workshop, Placebo; Behavioral · Other
Lead sponsor: The Zucker Hillside Hospital; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Concussion, Brain, Treatment, Aerobic Exercise, Inflammation, Depression, Anxiety
Interventions: High Dose Exercise; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 13 Years to 18 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Aurora, Colorado • Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Major Depressive Disorder, Recurrent, Mild, Depressive Disorder, Major
Interventions: Transcranial Magnetic Stimulation (TMS), Magnetic Resonance Spectroscopy and Imaging; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 13 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anxiety, Depression, Conduct Disorder, Stress
Interventions: Practicing the Opposite (PTO), Usual Clinical Care; Behavioral · Other
Lead sponsor: Harvard University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Concord, Massachusetts + 1 more

Conditions: Major Depressive Disorder
Interventions: Vilazodone; Viibryd, Paroxetine; Paxil; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression, Obsessive-Compulsive Disorder, Anxiety Depression
Interventions: NeuroStar Advanced TMS Therapy System; Device
Lead sponsor: Neuronetics; Other
Eligibility: 5 Years to 120 Years
Enrollment: 156,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Malvern, Pennsylvania

Search by objective public record fields.

Chronic Pelvic Pain and Education Skills Training for Women Veterans

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Stress Management Intervention for Mothers of Children With Cancer

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs

Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Safety Study of ORG 34517 for Major Depression With Psychotic Features

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Online and Shared Decision-Making Interventions to Engage Service Men and Women in Post-Deployment Mental Health Care

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety

POEM (Practice Of Embracing Each Moment) STUDY

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

Academic-Community EPINET (AC-EPINET)

From Intention to Action:Scoring Your College Goals

Modulating Exercise Dosage to Improve Concussion Recovery

Cortical Excitability and Inhibition in MDD

Digital Single Session Intervention for Youth Mental Health

Vilazodone for Treatment of Geriatric Depression

Retrospective Analyses of TrakStar Database